表紙
市場調查報告書

全基因組和外顯子組測序(WGES)市場:研究,臨床,腫瘤,病原體,Agribio,消費者-執行和顧問指南(包括Sars-cov-2全基因組測序)2020-2024年

Whole Genome and Exome Sequencing Markets by Research, Clinical, Tumor, Pathogen, Agribio & Consumer with Executive and Consultant Guides. (Including the Whole Genome Sequence of Sars-cov-2) 2020 to 2024

出版商 Howe Sound Research 商品編碼 943429
出版日期 內容資訊 英文 528 Pages
商品交期: 最快1-2個工作天內
價格
全基因組和外顯子組測序(WGES)市場:研究,臨床,腫瘤,病原體,Agribio,消費者-執行和顧問指南(包括Sars-cov-2全基因組測序)2020-2024年 Whole Genome and Exome Sequencing Markets by Research, Clinical, Tumor, Pathogen, Agribio & Consumer with Executive and Consultant Guides. (Including the Whole Genome Sequence of Sars-cov-2) 2020 to 2024
出版日期: 2020年06月20日內容資訊: 英文 528 Pages
簡介

該報告調查了全球全基因組和外顯子組測序(WGES)市場,包括市場規模,增長和限制,最新發展和發展,按應用,生物體和地區進行的市場分析,提供諸如競爭狀況和主要公司簡介之類的信息。

內容

i:戰略形勢分析和COVID-19的影響

ii:高管,市場營銷,銷售和業務開發人員指南

iii:管理顧問和投資顧問指南

第1章簡介和市場定義

  • 定義
    • 全基因組和外顯子組測序(WGES)
    • 調查與臨床
    • 臨床腫瘤
    • 臨床病原體
    • 農業/其他
    • D2C
  • 基因組學革命
  • 市場定義
    • 收入市場規模
  • 美國醫療市場和臨床實驗室:展望
    • 用於實驗室測試的美國Medicare支出
  • 基因組大小
    • 成本,價格,基因組大小,定價

第2章市場概述

  • 進入市場的公司
    • 設備製造商
    • 獨立實驗室:特殊/偏遠地區
    • 獨立實驗室:國家/地區
    • 獨立實驗室:分析
    • 國家/地區公共實驗室
    • 醫院實驗室
    • 醫生的實驗室
    • DTC實驗室
    • 測序實驗室
    • 審核機關
  • 市場,示例和注意事項
    • 面向消費者的兩種方法
    • 研究市場
    • 臨床理解生殖細胞和體細胞
    • 病原體檢測
    • Agribio的大生意
  • 產業結構
    • 醫院檢查份額
    • 規模經濟
    • 設備製造商的作用
    • 醫療保健行業的影響

第3章市場趨勢

  • 生長因子
    • 診斷因素
    • 其他代碼的解釋
    • 農業變化
    • 不孕治療技術的到來
    • 病原體問題
  • 抑制因子
    • 由於競爭加劇,價格降低
    • 成本低
    • 對醫療費用的擔憂
    • 健康欠佳
    • GMO反對運動
  • 測量順序
    • 由於成本降低而導致的產業結構變化
    • 當前NGS設備規格列表
    • Illumina
    • ION
    • Pacific Biosystems
    • Roche
    • SOLiD
    • Oxford Nanopore
    • 採用CRISPR作為靶序列
    • 新的測序技術等

第4章WGES的最新進展

  • 最近的發展

第5章 主要公司簡介

  • 10x Genomics, Inc.
  • 23andME Inc.
  • Abbott Diagnostics
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Admera Health, LLC
  • Agena Bioscience, Inc.
  • Agilent
  • Akonni Biosystems
  • Ancestry.com LLC
  • Anchor Dx
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocept, Inc.
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • Biolidics Ltd
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne
  • C2i Genomics
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Centogene
  • Chronix Biomedical
  • Circulogene
  • Clear Labs
  • Clinical Genomics
  • Complete Genomics, Inc.-A BGI Company
  • Cynvenio
  • Dante Labs
  • Datar Cancer Genetics Limited
  • Day Zero Diagnostics
  • Diasorin S.p.A.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Excellerate Bioscience
  • Exosome Diagnostics
  • Fabric Genomics
  • Fluidigm Corp
  • Freenome
  • FUJIFILM Wako Diagnostics
  • Fujirebio
  • Fulgent Genetics
  • GE Global Research
  • GE Healthcare Life Sciences
  • Gencove
  • Genedrive
  • GeneFirst Ltd.
  • Genetron Health (Beijing) Co., Ltd.
  • Genewiz
  • Genomic Health
  • Genomics England
  • Genomics Personalized Health (GPH)
  • GenomOncology
  • Genzyme Corporation
  • Grail, Inc.
  • Grifols
  • Guardant Health
  • Guardiome
  • HeiScreen
  • Helix
  • Helomics
  • Hologic
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • Human Longevity, Inc.
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Invitae Corporation
  • Invivoscribe
  • Karius
  • Macrogen
  • MDNA Life SCIENCES, Inc.
  • MDx Health
  • Medgenome
  • Meridian Bioscience
  • Mesa Biotech
  • MIODx
  • miR Scientific
  • MNG Labs
  • Molecular MD
  • NantHealth, Inc.
  • Natera
  • Nebula Genomics
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd.
  • Omega Bioservices
  • OncoDNA
  • OpGen
  • ORIG3N, Inc.
  • Origene Technologies
  • Oxford Nanopore Technologies
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Protagen Diagnostics
  • Qiagen Gmbh
  • Quantumdx
  • Regeneron
  • Roche Molecular Diagnostics
  • Roswell Biotechnologies
  • Seegene
  • Sequencing.com
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc.
  • SkylineDx
  • Stratos Genomics
  • Sure Genomics, Inc.
  • Sysmex
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Veritas Genetics
  • Volition

第六章世界市場

  • 按國家
  • 通過申請
  • 生物

第7章市場分析:按用法

  • 調查
  • 臨床人體
  • 臨床腫瘤
  • 臨床病原體
  • D2C
  • 農業/其他

第8章市場分析:按有機體

  • 人類
  • 病原
  • 其他生物

第9章全基因組測序的未來圖像

附錄

  • i。美國醫療保險制度:2020年1月的實驗室費用時間表
  • SARS-CoV-2的II全基因組序列
  • III調查方法
目錄

OVERVIEW:

The COVID Pandemic has created a surge in Whole Genome Sequencing of Pathogens but cancer related activity has suffered. Find out all about it in the comprehensive report of Whole Genome Sequencing. The complete genome of the COVID virus is included as an example of the work being done.

Will all newborns receive Whole Genome Sequencing at birth? How fast will Direct to Consumer Testing grow? What sequencing technology will take the lead? What's holding the industry back? Where are the over 800 locations that have high throughput devices?

Our facts and support = Your success.

A plummeting of costs for Whole Genome Sequencing is creating a gold rush for market players. New consumers, new technologies, new specializations. In a situation reminiscent of the birth of the internet industry a wide range of well funded players are racing for market share on a truly global stage. The report forecasts the market size out to 2023. The report includes detailed breakouts for 14 countries and 5 regions.

Tumor Cell Sequencing? Direct to Consumer? Gene Expression? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities, and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.

All report data is available in Excel format on request. Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Whole Genome Sequencing Market - Strategic Situation Analysis & COVID Impact

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1. Whole Genome Sequencing Definition In This Report
    • 1.1.1. Whole and Exome Sequencing
    • 1.1.2. Research and Clinical
    • 1.1.3. Clinical Tumor
    • 1.1.4. Clinical Pathogen
    • 1.1.5. Agri/Other
    • 1.1.6. Direct to Consumer
  • 1.2. The Genomics Revolution
  • 1.3. Market Definition
    • 1.3.1. Revenue Market Size
  • 1.4. U.S. Medical Market and laboratory Testing - Perspective
    • 1.4.1. U.S. Medicare Expenditures for laboratory testing
  • 1.5. Sizing the Genome-Not What You Think
    • 1.5.1. Cost, Price and Genome Size, Pricing Practice

1A GLOBAL LISTING OF HIGH THROUGHPUT SEQUENCING ESTABLISHMENTS INSTALLED BASE-Location & Contacts

2. Market Overview

  • 2.1. Market Participants Play Different Roles
    • 2.1.1. Instrument Manufacturer
    • 2.1.2. Independent lab specialized/esoteric
    • 2.1.3. Independent lab national/regional
    • 2.1.4. Independent lab analytical
    • 2.1.5. Public National/regional lab
    • 2.1.6. Hospital lab
    • 2.1.7. Physician lab
    • 2.1.8. DTC Lab
    • 2.1.9. Sequencing Labs
    • 2.1.10. Audit body
  • 2.2. Whole Genome Sequencing -Markets, Examples and Discussion
    • 2.2.1. Direct to Consumer-Two Approaches
      • 2.2.1.1. The New Age of Medical Information
      • 2.2.1.2. Dangers in DTC-WGS-Health Costs and Regulation
      • 2.2.1.3. Newborn and Prenatal-A Brave New World
      • 2.2.1.4. DTC-How Many Segments?
    • 2.2.2. Research Markets
      • 2.2.2.1. Research Funding and Capital Expense
      • 2.2.2.2. WGS Datasets Preferred
      • 2.2.2.3. Existing research repurposed
      • 2.2.2.4. Organism Wide Market
      • 2.2.2.5. Service Suppliers Respond
    • 2.2.3. Clinical-Understanding Germline and Somatic
      • 2.2.3.1. Somatic-Chasing Mutations and Pharmacogenomics
    • 2.2.4. Pathogen Testing
      • 2.2.4.1. The Hepatitis C Story
      • 2.2.4.2. Will the Microbiology Department Disappear?
    • 2.2.5. AgriBio-Big Business
      • 2.2.5.1. GMO is Here to Stay
      • 2.2.5.2. WGS Benefits and Risks
      • 2.2.5.3. The New Agriculture
  • 2.3. Industry Structure
    • 2.3.1. Hospital's Testing Share
    • 2.3.2. Economies of Scale
    • 2.3.3. Instrument Manufacturer Role
    • 2.3.4. Healthcare Industry Impacts-Still Struggling
      • 2.3.4.1. Can the Healthcare Industry Adapt?
      • 2.3.4.2. Genetic Counselling as an Industry
      • 2.3.4.3. WGES Adoption and Cannibalization
      • 2.3.4.4. The Meaning of Grail

3. Market Trends

  • 3.1. Factors Driving Growth
    • 3.1.1. Diagnostic Factors
    • 3.1.2. Interpreting the Code Otherwise
    • 3.1.3. Changes in Agriculture
    • 3.1.4. Fertility Technology Comes of Age
    • 3.1.5. Pathogen Challenges
  • 3.2. Factors Limiting Growth
    • 3.2.1. Increased Competition Lowers Price
    • 3.2.2. Lower Costs
    • 3.2.3. Healthcare Cost Concerns Curtail Growth
    • 3.2.4. Wellness has a downside
    • 3.2.5. GMO Opposition Movement
  • 3.3. Sequencing Instrumentation
    • 3.3.1. Instrumentation Tenacity
    • 3.3.2. Declining Cost Changes Industry Structure
    • 3.3.3. LISTING of CURRENT NGS INSTRUMENT SPECIFICATIONS
    • 3.3.4. Illumina
    • 3.3.5. ION
    • 3.3.6. Pacific Biosystems
    • 3.3.7. Roche 454
    • 3.3.8. SOLiD
    • 3.3.9. Oxford Nanopore
      • 3.3.9.1. What is Oxford Nanopore Sequencing?
      • 3.3.9.2. What can Oxford Nanopore Sequencingt be used for?
      • 3.3.9.3. Oxford Nanopore Products
    • 3.3.10. Long Reads-Further Segmentation
    • 3.3.11. Linked Reads
    • 3.3.12. Targeted Sequencing Adopts CRISPR
    • 3.3.13. New Sequencing Technologies
      • 3.3.13.1. RNAP sequencing
      • 3.3.13.2. In vitro virus high-throughput sequencing
      • 3.3.13.3. Tunnelling currents DNA sequencing
      • 3.3.13.4. Sequencing by hybridization
      • 3.3.13.5. Sequencing with mass spectrometry
      • 3.3.13.6. Microfluidic Sanger sequencing
      • 3.3.13.7. Microscopy-based techniques

4. WGES Recent Developments

  • 4.1. Recent Developments-Importance and How to Use This Section
    • 4.1.1. Importance of These Developments
    • 4.1.2. How to Use This Section
      • Illumina Achieves First FDA EAU for NGS-Based SARS-CoV-2 Test
      • C2i Genomics to Launch Trials for MRD Detection Tech
      • Roche Acquires Sequencing Company Stratos Genomics
      • UK COVID-19 Sequencing Consortium Launches With £20M in Government, Wellcome Trust Funding
      • Invitae Acquires Three Companies: YouScript, Genelex, Diploid
      • Experience From Centralized Genomic Medicine Lab
      • MGI to Enable $100 Human Genome
      • Nebula Genomics offers $299 WGS
      • Team to Study Campylobacter Omics
      • Veritas Genetics Restarts US Business
      • NEOGEN, Gencove partner to advance animal genomics
      • UK Whole-Genome Sequencing Project Obtains £200M
      • WGS may help with disease outbreaks
      • Veritas Cuts WGS Price by 40%
      • Dante Labs Launches GenomeL, Long Reads Human Whole Genome Sequencing
      • Machine-learning system used to diagnose genetic diseases
      • Whole Genome Sequencing for healthy creates controversy
      • 100,000 whole genomes sequenced in the NHS
      • Nebula Genomics Offers FREE Whole Genome Sequencing
      • Veritas Genetics has time limited WGS offer for $199
      • Veritas Genetics Launches Two New Whole Genome Sequencing Products
      • BGI unveils a powerful new sequencer
      • State of California Funds $2M Whole-Genome Sequencing Pilot

5. Profiles of Key Companies

  • 10x Genomics, Inc.
  • 23andME Inc.
  • Abbott Diagnostics
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Admera Health, LLC
  • Agena Bioscience, Inc.
  • Agilent
  • Akonni Biosystems
  • Ancestry.com LLC
  • Anchor Dx
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocept, Inc.
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • Biolidics Ltd
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne
  • C2i Genomics
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Centogene
  • Chronix Biomedical
  • Circulogene
  • Clear Labs
  • Clinical Genomics
  • Complete Genomics, Inc.-A BGI Company
  • Cynvenio
  • Dante Labs
  • Datar Cancer Genetics Limited
  • Day Zero Diagnostics
  • Diasorin S.p.A.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Excellerate Bioscience
  • Exosome Diagnostics
  • Fabric Genomics
  • Fluidigm Corp
  • Freenome
  • FUJIFILM Wako Diagnostics
  • Fujirebio
  • Fulgent Genetics
  • GE Global Research
  • GE Healthcare Life Sciences
  • Gencove
  • Genedrive
  • GeneFirst Ltd.
  • Genetron Health (Beijing) Co., Ltd.
  • Genewiz
  • Genomic Health
  • Genomics England
  • Genomics Personalized Health (GPH)
  • GenomOncology
  • Genzyme Corporation
  • Grail, Inc.
  • Grifols
  • Guardant Health
  • Guardiome
  • HeiScreen
  • Helix
  • Helomics
  • Hologic
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • Human Longevity, Inc.
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Invitae Corporation
  • Invivoscribe
  • Karius
  • Macrogen
  • MDNA Life SCIENCES, Inc.
  • MDx Health
  • Medgenome
  • Meridian Bioscience
  • Mesa Biotech
  • MIODx
  • miR Scientific
  • MNG Labs
  • Molecular MD
  • NantHealth, Inc.
  • Natera
  • Nebula Genomics
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd.
  • Omega Bioservices
  • OncoDNA
  • OpGen
  • ORIG3N, Inc.
  • Origene Technologies
  • Oxford Nanopore Technologies
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Protagen Diagnostics
  • Qiagen Gmbh
  • Quantumdx
  • Regeneron
  • Roche Molecular Diagnostics
  • Roswell Biotechnologies
  • Seegene
  • Sequencing.com
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc.
  • SkylineDx
  • Stratos Genomics
  • Sure Genomics, Inc.
  • Sysmex
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Veritas Genetics
  • Volition

6. The Global Market for Whole Genome Sequencing

  • 6.1. Global Market Overview by Country
    • 6.1.1. Table-Global Market by Country
    • 6.1.2. Chart - Global Market by Country
  • 6.2. Global Market by Application - Overview
    • 6.2.1. Table-Global Market by Application
    • 6.2.2. Chart-Global Market by Application-Base/Final Year Comparison
    • 6.2.3. Chart-Global Market by Application-Base Year
    • 6.2.4. Chart-Global Market by Application-Final Year
    • 6.2.5. Chart-Global Market by Application-Share by Year
    • 6.2.6. Chart-Global Market by Application-Segment Growth
  • 6.3. Global Market Organism - Overview
    • 6.3.1. Table-Global Market by Organism
    • 6.3.2. Chart-Global Market by Organism-Base/Final Year Comparison
    • 6.3.3. Chart-Global Market by Organism-Base Year
    • 6.3.4. Chart-Global Market by Organism-Final Year
    • 6.3.5. Chart-Global Market by Organism-Share by Year
    • 6.3.6. Chart-Global Market by Organism-Segment Growth

7. Global Whole Genome Sequencing Markets-By Application

  • 7.1. Research
    • 7.1.1. Table Research-by Country
    • 7.1.2. Chart - Research Growth
  • 7.2. Clinical Human
    • 7.2.1. Table Clinical Human-by Country
    • 7.2.2. Chart - Clinical Human Growth
  • 7.3. Clinical Tumor
    • 7.3.1. Table Clinical Tumor-by Country
    • 7.3.2. Chart - Clinical Tumor Growth
  • 7.4. Clinical Pathogen
    • 7.4.1. Table Clinical Pathogen-by Country
    • 7.4.2. Chart - Clinical Pathogen Growth
  • 7.5. Direct to Consumer
    • 7.5.1. Table Direct to Consumer-by Country
    • 7.5.2. Chart-Direct to Consumer Growth
  • 7.6. Agriculture/Other
    • 7.6.1. Table Agriculture/Other-by Country
    • 7.6.2. Chart-Agriculture/Other Growth

8. Global Whole Genome Sequencing Markets-by Organism

  • 8.1. Human
    • 8.1.1. Table Human-by Country
    • 8.1.2. Chart - Human Growth
  • 8.2. Pathogen
    • 8.2.1. Table Pathogen-by Country
    • 8.2.2. Chart - Pathogen Growth
  • 8.3. Other Organism
    • 8.3.1. Table Other Organism-by Country
    • 8.3.2. Chart - Other Organism Growth

9. Vision of the Future of Whole Genome Sequencing

Appendices

  • I. United States Medicare System: January 2020 laboratory Fees Schedule
  • II The Whole Genome Sequence of SARS-CoV-2
  • III Methodology
  • II.1. Authors
  • II.2. Sources

Table of Tables

  • Table 1: The Base Pairs
  • Table 2: Most Common Traditional Genetic Disorders
  • Table 3: Lab Spending 2014 to 2024
  • Table 4: List of GLOBAL SEQUENCING LOCATIONS
  • Table 5: Market Players by Type
  • Table 6: The Different Markets for Whole Genome Sequencing
  • Table 7: DTC Sub Segments
  • Table 8: Roles of WGS in AgriBio
  • Table 9: The Factors Driving Growth
  • Table 10: Factors Limiting Growth
  • Table 11: - Listing of Current NGS Instrument Specifications
  • Table 12: Six New Sequencing Technologies
  • Table 13: - Global Companion Diagnostic Market by Region
  • Table 14: Global Market by Application
  • Table 15: Global Market by Organism
  • Table 16: Research by Country
  • Table 17: Clinical Human by Country
  • Table 18: Clinical Tumor by Country
  • Table 19: Clinical Pathogen by Country
  • Table 20: Direct to Consumer by Country
  • Table 21: Agriculture/Other by Country
  • Table 22: Human by Country
  • Table 23: Pathogen by Country
  • Table 24: Other Organism by Country
  • Table 25: 2020 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1: Clinical Lab Spending 2014 to 2024
  • Figure 2: Size of Genome for Various Species
  • Figure 3: - Cost To Sequence a Human Genome
  • Figure 4: Base Year Country Market Share Chart
  • Figure 5: CDx Market by Application - Base vs. Final Year
  • Figure 6: CDx Market by Application Base Year
  • Figure 7: CDx Market by Application Final Year
  • Figure 8: Application Type Share by Year
  • Figure 9: by Application Segment Growth
  • Figure 10: by Organism - Base vs. Final Year
  • Figure 11: by Organism Market Base Year
  • Figure 12: by Organism Market Final Year
  • Figure 13: by Organism Share by Year
  • Figure 14: by Organism Segment Growth
  • Figure 15: Research Growth
  • Figure 16: Clinical Human Growth
  • Figure 17: Clinical Tumor Growth
  • Figure 18: Clinical Pathogen Growth
  • Figure 19: Direct to Consumer Growth
  • Figure 20: Agriculture/Other Growth
  • Figure 21: Human Growth
  • Figure 22: Pathogen Growth
  • Figure 23: Other Organism Growth